CARTITUDE-2

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

  • Myeloma Service
  • 21-009

What's the purpose of the trial?

The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.

Trial status

Accepting patients

Phase
Phase 2
Enrollment
237
Last Updated
3 days ago
Patient Screener

Participating Centers

There are 29 centers participating in this trial. Enter a location below to find the closest center.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Newly Diagnosed, Not Eligible or Refusing Stem Cell Transplant

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.